Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of transcutaneous auricular vagus nerve stimulation in patients with narcolepsy type 1 (TARGET-2): study protocol for a randomised, double-blind, sham-controlled trial.

BMJ open·2026
Same author

Discovery and mutasynthetic optimization of ansatrienin B: A new broad-spectrum inhibitor against RNA viruses.

Acta pharmaceutica Sinica. B·2026
Same author

Risk Factors for Postoperative Complications in Patients Reoperated for Persistent/Recurrent DTC.

The Journal of surgical research·2026
Same author

Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.

Annals of hematology·2026
Same author

Identifying NOTCH signaling-specialized hematopoietic supportive subpopulation from mesenchymal stem cells.

Stem cell research & therapy·2026
Same author

Optimized post-GWAS analysis identifies therapeutic targets for essential thrombocythemia and polycythemia vera.

Communications medicine·2026
Same journal

An IL-15 fusion with albumin-binding domain boosts Immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1/2.

Cancer letters·2026
Same journal

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same journal

Aldo-keto Reductase Family 1 Member C3 Suppresses Glioma Progression via Inhibiting Prostaglandin D2-Dependent RhoA/ROCK Signaling.

Cancer letters·2026
Same journal

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Cancer letters·2026
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
See all related articles

Related Experiment Video

Updated: Sep 6, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.6K

Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.

Yangping Wu1, Jingliao Zhang1, Xiaofan Zhu1

  • 1Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Cancer Letters
|June 28, 2022
PubMed
Summary
This summary is machine-generated.

PROteolysis TArgeting Chimeras (PROTACs) offer a novel therapeutic approach for hematologic malignancies by degrading target proteins. PROTACs show promise for treating "undruggable" cancers, despite design and clinical challenges.

Keywords:
Hematological malignanciesOptimizationPROTACPros and consTargeted protein degradation

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.1K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Related Experiment Videos

Last Updated: Sep 6, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.6K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.1K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Area of Science:

  • Biochemistry
  • Oncology
  • Drug Discovery

Background:

  • PROteolysis TArgeting Chimeras (PROTACs) leverage the ubiquitin-proteasome system for targeted protein degradation.
  • PROTACs present a significant advancement over traditional therapeutics for hematologic malignancies.
  • They offer enhanced efficacy, selectivity, and improved side effect profiles.

Purpose of the Study:

  • To review PROTACs with demonstrated preclinical and clinical potential in hematologic malignancies over the past five years.
  • To provide an overview of PROTACs' mechanism of action and recent breakthroughs.
  • To discuss the advantages and disadvantages of PROTACs in therapeutic applications.

Main Methods:

  • Literature review focusing on PROTACs in hematologic malignancies.
  • Analysis of preclinical efficacy and clinical trial data.
  • Discussion of design, synthesis, and evaluation challenges.

Main Results:

  • PROTACs show significant promise in degrading oncogenic proteins, including previously
  • undruggable
  • targets.
  • Recent studies highlight PROTACs' efficacy and selectivity in preclinical models of hematologic cancers.
  • Several PROTACs are advancing toward or are in clinical trials for these indications.

Conclusions:

  • PROTACs represent a powerful therapeutic strategy for hematologic malignancies, addressing unmet needs.
  • Optimization of PROTACs is crucial for overcoming current challenges in clinical application.
  • Continued development and clinical trials are expected to benefit patients with hematologic malignancies.